Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Rossari Biotech's Board approved FY26 audited results showing consolidated revenue of Rs 23,963.65 million (up 15% from Rs 20,802.94 million) and PAT of Rs 1,492.13 million (up 9.4% from Rs 1,363.78 million). Basic EPS stands at Rs 26.95. Q4 saw a one-time gain of Rs 192.67 million from sale of Kanjurmarg office. The Board declared final dividend of Rs 0.50 per share (25% on Rs 2 face value), subject to shareholder approval at AGM. Mr. Udeypaul Singh Gill was appointed as Non-Executive Independent Director for 3 years from April 28, 2026. Additionally, 8,250 equity shares were allotted under ESOP 2019 at Rs 425 exercise price, and a new R&D facility was set up in Navi Mumbai. The planned capacity expansion project is being rescheduled to a phased implementation over two years due to evolving market conditions.
Positive signals include strong revenue growth, clean audit opinion, dividend declaration, and new R&D setup. The delayed capacity expansion and one-time office sale gain in Q4 are neutral-to-mildly negative for near-term guidance.